GlassScriptPhysician profile
Ravi Kant
NPI 1720242183
$8,206.15
in general payments reported to CMS, 2019-2025
53 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $485 · 2021: $1,153 · 2022: $1,613 · 2023: $1,571 · 2024: $1,060 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,090.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $580.16 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $535.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $513.56 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $504.71 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $463.58 | 2019-2025 | |
| Insulet Corporation | $421.45 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $393.38 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $340.75 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $266.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $204.99 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $167.65 | 2020-2024 | Strensiq |
| Recordati_rare_diseases_inc. | $166.73 | 2020-2025 | Isturisa, Signifor Lar |
| Dexcom, INC. | $163.87 | 2021-2024 | Dexcom G6 Transmitter |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.21 | 2019-2025 | |
| Medtronic, INC. | $156.52 | 2021-2025 | Minimed 780g |
| Antares Pharma, INC. | $150.48 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $127.34 | 2020-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $124.93 | 2019-2024 | Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $111.70 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $111.69 | 2020-2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $111.24 | 2021-2023 | |
| Smith+Nephew, INC. | $109.61 | 2024 | Grafix Pl |
| Sequel Med Tech, LLC | $90.68 | 2025 | Twiist |
| Clarus Therapeutics INC. | $83.95 | 2021 | |
| Madrigal Pharmaceuticals | $79.28 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $60.10 | 2021-2022 | |
| Zealand Pharma US, INC. | $57.97 | 2021-2022 | |
| Radius Health, INC. | $56.58 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $54.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $47.84 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $46.41 | 2023 | Imcivree |
| Becton, Dickinson and Company | $41.82 | 2019-2022 | |
| Amryt Pharma Holdings LTD | $38.72 | 2022-2023 | Myalept |
| Grt US Holding, INC. | $30.48 | 2022 | |
| Medtronic Minimed, INC. | $28.32 | 2019-2020 | |
| Cequr Corporation | $26.49 | 2022-2023 | Cequr Simplicity |
| Nevro Corp. | $24.52 | 2022 | |
| Eisai INC. | $22.57 | 2019 | |
| Averitas Pharma INC. | $21.49 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $20.47 | 2024 | |
| Aytu Biopharma, INC. | $19.84 | 2019 | |
| Almatica Pharma LLC | $19.65 | 2024 | Teriparatide |
| Mannkind Corporation | $17.85 | 2023 | Afrezza |
| Verity Pharmaceuticals INC. | $17.42 | 2025 | Tlando |
| Valeritas, INC. | $16.09 | 2019 | |
| Shire North American Group INC | $15.83 | 2019 | |
| Eusa Pharma (US) LLC | $15.23 | 2022 | |
| Exact Sciences Corporation | $14.88 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.82 | 2024 | Trelegy Ellipta |
| Acerus Pharmaceuticals Corporation | $14.45 | 2022 | |
| Tolmar, INC. | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Kant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.